DES arena THE CURRENT APPROACH TO DES MARKET IS BASED ON DRUG Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA

Chemical union with a monomer of Triflusal Active APPROACH IS LEVERAGED Paclitaxel Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA P5 – Acrylic Polymer Chemical union with a monomer of Triflusal

Chemical union with a monomer of Triflusal Active APPROACH IS LEVERAGED Simvastatin Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA P5 – Acrylic Polymer Chemical union with a monomer of Triflusal

PLATFORM APOLO 3 STENT STENT APOLO3 Stainless Steel Open Cell Structure Diameters 3,00-4,50mm High Uniform Radial Force Superior Flexibility Low Recoil (1%) Good trackability 5F Guiding Catheter Stainless Steel Open Cell Structure Diameters 2,00-2,75mm High Uniform Radial Force Superior Flexibility Low Recoil (1%) Good trackability 5F Guiding Catheter Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA

PLATFORM APOLO 3 STENT STENT APOLO3 - WIDTH Superior Flexibility 0,0045” 0,0041” Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA 0,0033” 0,0033” 0,0049” 0,0045” Superior Flexibility Entry Profile 0,017’’

PLATFORM APOLO 3 STENT STENT APOLO3 – STRUT THICKNESS Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA 0,0045” 0,0037” Strut Thickness: 0.0045” Excellent Crossing Profile (0.038” - 0,041’’) Strut Thickness: 0.0037” Excellent Crossing Profile (0.034” - 0,038’’)

PLATFORM APOLO 3 STENT STENT APOLO3 – CROWNS AND CONNECTORS 6 Crowns Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA 6 Crowns 3 Connectors in spiral shape Superior flexibility High Uniform Radial Force Low Recoil (1%)

PLATFORM APOLO 3 STENT STENT APOLO3 – CROWNS AND CONNECTORS 5 Crowns Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA 5 Crowns 2 Connectors in spiral shape Superior flexibility High Uniform Radial Force Low Recoil (1%)

PLATFORM APOLO 3 STENT PHYSICO-MECHANICAL PROPERTIES (COATING) SMOOTHNESS Propiedades físico-mecánicas (recubrimiento): traduïr!! No turbulence No roughness No friction Pre-crimping Post-crimping The Polymer is fixed to the stent thanks to a unique and proprietary Iberhospitex-Cordynamic process

PLATFORM APOLO 3 STENT PHYSICO-MECHANICAL PROPERTIES (COATING) NO CRACK-BRIDGING Propiedades físico-mecánicas (recubrimiento): traduïr!! A B No modification of mechanical integrity Surface protection Non crackable

PLATFORM APOLO 3 STENT PHYSICO-MECHANICAL PROPERTIES (COATING) NO STICKY traduïr B Easy balloon withdrawal Non fragment detachment Drug release homogeneity

Chemical union with a monomer of Triflusal IRIST APPROACH IS LEVERAGED Simvastatin Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA P5 – Acrylic Polymer Chemical union with a monomer of Triflusal

Copolymer of methacrylic monomer containing Triflusal & butyl acrylate High molecular weight High hydrolytic stability Good drug loading High biocompatibility Biostable Antiplatelet Anti-inflammatory The Polymer is patented and developed for DES applications by a co-development between Laboratorios Uriach and Iberhospitex-Cordynamic

POLYMER P-5 BIOSTABLE Triflusal Release % HTB Released Days Traduir quadre HTB liberado % HTB Released Days

Compatibility of P-5 Polymer with different drugs GOOD DRUG SUPPORT Compatibility of P-5 Polymer with different drugs Traduïr i disenyar quadre % Drug % Polymer

POLYMER P-5 BIOLOGICAL PROPERTIES OF TRIFLUSAL NON PLATELET ADHESION Si es creu oportú arreglar fotos Control: Pre-incubation with Platelet-rich plasma Control: Post-incubation with Platelet-rich plasma Control: Post-incubation with Platelet-rich plasma Polymer P-5: Pre-incubation With platelet-rich plasma Polymer P-5: Pre-incubation With platelet-rich plasma Polymer P-5: Post-incubation With platelet-rich plasma Polymer P-5: Post-incubation With platelet-rich plasma

POLYMER P-5 BIOCOMPATIBLE: OSTEOBLASTS AND FIBROBLASTS BIOLOGICAL PROPERTIES OF TRIFLUSAL BIOCOMPATIBLE: OSTEOBLASTS AND FIBROBLASTS Control Polymer P-5 Normal cell adhesion Standard cell growing Normal morphology

Polímer Pattern (Cordis) Polímer Pattern (Cordis) POLYMER P-5 BIOLOGICAL PROPERTIES OF TRIFLUSAL BIOCOMPATIBLE: EX-VIVO PLATELET DEPOSITION (Badimon’s Camera) Camera diameter: 0.2cm 212/s DacrOn 10 20 30 40 * p<0.05 vs Dacron Platelet Adhesion (x10 6 /cm 2 ) Polímer Pattern (Cordis) Active’s polymer Camera diameter: 0.1cm 1690/s 10 20 30 40 * Platelet Adhesion (x10 6 /cm 2 ) DacrOn p<0.05 vs Dacron Polímer Pattern (Cordis) Active’s polymer Non thrombogenic Source: Catalan Institute of Cardiovascular Sciences (Barcelona)

Polímer Pattern (Cordis) Polímer Pattern (Cordis) POLYMER P-5 BIOLOGICAL PROPERTIES OF TRIFLUSAL BIOCOMPATIBLE: IN-VITRO PLATELET ADHESION (Static Conditions) HEPARINE * * P<0.05 vs Cordis Dacron Polímer Pattern (Cordis) Active’s polymer 5.00 5.25 5.50 5.75 6.00 Platelet Adhesion (x10 6 /cm 2 ) * Dacron Active’s polymer 2.00 2.25 2.50 2.75 3.00 Platelet Adhesion (x10 6 /cm 2 ) CITRATE Polímer Pattern (Cordis) Non thrombogenic Source: Catalan Institute of Cardiovascular Sciences (Barcelona)

Chemical union with a monomer of Triflusal ACTIVE APPROACH IS LEVERAGED Paclitaxel Falten les 2 primeres pàgines: STENT IRIST Inhibición de la restenosis intra-stent mediante simvastatina FASE PRE-CLÍNICA I ESQUEMA DE FÁRMACO-POLÍMERO-PLATAFORMA P5 – Acrylic Polymer Chemical union with a monomer of Triflusal

Paclitaxel - Effective anti-proliferative drug Numerous studies demonstrated the positive effects of Paclitaxel on inhibiting Smooth Muscle Cell (SMC) proliferation and migration. Paclitaxel supports an uniform drug distribution and suppresses the formation of neointimal hyperplasia due to its lipophilic property.

DRUG: PACLITAXEL